Key Takeaways
- • Advanced Medical Solutions (AMS Group) confirmed formal takeover discussions with US private equity firm TA Associates Management LP, with reports indicating a potential offer around 280p per share, triggering mandatory "offer period" disclosure requirements under Takeover Code regulations.
- • AMS Group's share price surged following the public confirmation of takeover talks, reflecting investor appetite for a sale of the London-listed medical device manufacturer, which produces surgical brands including LiquiBand and Resorba.
- • The company reported strong financial momentum entering negotiations, with full-year revenues up 29% to approximately £229 million, positioning it as an attractive acquisition target for large-cap private equity investors.
- • Multiple private equity firms have circled AMS Group in recent months, including Inflexion and Bridgepoint, though TA Associates has emerged as the lead bidder in formal discussions as of April 2026.
- • AMS Group operates in the medical technology sector focused on tissue-healing surgical products, with a market capitalization exceeding £500 million prior to takeover confirmation.
Summary
Advanced Medical Solutions Group PLC has confirmed it is engaged in discussions with TA Associates Management LP, a prominent US private equity firm, regarding a potential takeover of the company. The announcement placed AMS Group into an "offer period" under Takeover Code protocols, triggering formal disclosure obligations for shareholders and establishing a structured regulatory framework for negotiations. Reports indicate TA Associates is considering an offer in the region of 280p per share, valuing the acquisition at a significant premium to recent trading levels.
The confirmation of formal talks has attracted considerable market attention, with AMS Group's share price rising following the disclosure. This investor enthusiasm reflects confidence in both the company's operational performance and the likelihood of a successful transaction. The medical device manufacturer has demonstrated robust financial performance entering the sale process, reporting full-year revenues up 29% to nearly £229 million in its most recent results announcement, establishing a strong operational baseline for valuation discussions.
AMS Group manufactures a portfolio of tissue-healing and surgical products, including established brands such as LiquiBand and Resorba, serving hospital and surgical markets globally. The company's market capitalization exceeds £500 million, positioning it within the mid-market acquisition sweet spot for large institutional private equity investors seeking defensible healthcare technology assets with demonstrated growth trajectories.
The takeover process has attracted attention from multiple buyout firms over recent months, with Inflexion and Bridgepoint previously reported to be studying the company. TA Associates' progression to formal negotiations and public confirmation of talks signals a competitive process likely to generate shareholder value and potentially attract alternative bidders. The regulatory framework established through the Takeover Code offer period will govern the pace and transparency of negotiations through completion or termination of discussions.
The confirmation of formal talks has attracted considerable market attention, with AMS Group's share price rising following the disclosure. This investor enthusiasm reflects confidence in both the company's operational performance and the likelihood of a successful transaction. The medical device manufacturer has demonstrated robust financial performance entering the sale process, reporting full-year revenues up 29% to nearly £229 million in its most recent results announcement, establishing a strong operational baseline for valuation discussions.
AMS Group manufactures a portfolio of tissue-healing and surgical products, including established brands such as LiquiBand and Resorba, serving hospital and surgical markets globally. The company's market capitalization exceeds £500 million, positioning it within the mid-market acquisition sweet spot for large institutional private equity investors seeking defensible healthcare technology assets with demonstrated growth trajectories.
The takeover process has attracted attention from multiple buyout firms over recent months, with Inflexion and Bridgepoint previously reported to be studying the company. TA Associates' progression to formal negotiations and public confirmation of talks signals a competitive process likely to generate shareholder value and potentially attract alternative bidders. The regulatory framework established through the Takeover Code offer period will govern the pace and transparency of negotiations through completion or termination of discussions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.